Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioAlliance Pharma Announces Shareholders’ Meeting and Appointment of Independant Board Members

Published: Monday, July 01, 2013
Last Updated: Monday, July 01, 2013
Bookmark and Share
As a result of the shareholder’s meeting, Dr Russell Greig and Danièle Guyot-Caparros have been appointed as independent Board Members.

Dr Russell Greig holds a PhD in biochemistry from the University of Manchester. He held strategic positions at GlaxoSmithKline (GSK) for nearly three decades, notably as President of GSK Pharmaceuticals International from 2003 to 2008 and as a member of GSK Corporate Executive Team. Most recently, he served as President of SR One, GSK’s Corporate Venture Group. Since 2012, Russell has been a permanent guest member of the Board of Directors and has brought particular expertise to the Company in the area of Strategic Planning and Corporate Development.

Danièle Guyot-Caparros graduated from the Ecole Supérieure de Commerce of Nancy in finance and accounting. Following international missions in Audit, she joined Rhone Poulenc (now Sanofi) where she has held different positions with an increasing scope of responsibilities in finance on a European level and in business planning and performance monitoring on a worldwide level. Danièle has been working as a consultant specialized in life sciences and healthcare areas for 5 years.

“We are delighted to have Danièle and Russell joining our Board. Their appointment is in line with the Board’s expansion to international profiles and reinforces its skills in finance and strategy areas as well as its expertise in the pharmaceutical and biotechnology areas,” declared Judith Greciet, CEO of BioAlliance Pharma.

“I would like to join Judith in welcoming Danièle and Russell and warmly thank both departing members of the Board of Directors, Catherine and Michel, who brought their great professional experience to the Company these past few years. With its various backgrounds and skills, the new Board will actively pursue its role in defining and implementing the Company’s strategy and supporting its management team,” added Patrick Langlois, Chairman of the Board of Directors of BioAlliance Pharma.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioAlliance Pharma Expands and Strengthens Its Industrial Property Assets
BioAlliance Pharma SA was granted two patents by the American and Japanese Offices protecting two of its products; Oravig® (miconazole) and Sitavig® (acyclovir).
Friday, July 12, 2013
BioAlliance Pharma to Continue its Phase III Clinical Trial with Livatag®
The Data and Safety Monitoring Board (DSMB) has again recommended continuing the ReLive Phase III trial without modification.
Tuesday, May 14, 2013
BioAlliance Pharma’s Sitavig® Receives Market Authorization in the US
Authorization from the U.S. FDA for Sitavig® in the treatment of recurring Herpes labialis, marking the successful conclusion to the assessment procedure carried out by the American authorities.
Tuesday, April 16, 2013
BioAlliance Announces Phase I Trial for Fentanyl Lauriad® and the Submission of a Clonidine Lauriad® Phase II Clinical Trial Application
This clinical trial will evaluate the plasma pharmacokinetic parameters of Fentanyl Lauriad® in healthy volunteers.
Tuesday, October 13, 2009
BioAlliance Announces Positive Preliminary Pivotal Phase III Results in Herpes Labialis with Acyclovir Lauriad®
Study compared the efficacy and safety of a single dose acyclovir Lauriad® 50mg MBT versus matching placebo in recurrent oro-facial herpes.
Thursday, August 27, 2009
BioAlliance Pharma Submits Clinical Trial New Drug Application
Company announces submission of a Fentanyl Lauriad® clinical trial application to the French Drug Agency and approval by the Ethics Committee.
Wednesday, July 29, 2009
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!